ArticleIndian journal of ophthalmology2022
Vogt Koyanagi Harada disease following a recent COVID-19 infection.
Article in Indian journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Acute interstitial nephritis and probable Vogt-Koyanagi-Harada disease following COVID-19 infection: a case report.Journal of medical case reports · 2025Article
- Bilateral Exudative Retinal Detachments and Panuveitis in a Patient with Multiple Myeloma.Ocular immunology and inflammation · 2024Article
- Effect of the COVID-19 pandemic on Vogt-Koyanagi-Harada disease.Scientific reports · 2024Article
- New-onset or relapse of uveitis after rapid spreading of COVID-19 infection in China and risk factor analysis for relapse.BMC ophthalmology · 2024Article
- Vogt-Koyanagi-Harada disease after SARS-CoV-2 infection: Case report and literature review.Immunity, inflammation and disease · 2024Review
- Bibliometric analysis of the Vogt‒Koyanagi‒Harada disease literature.International ophthalmology · 2023Article
- Vogt-Koyanagi-Harada Disease and COVID.Journal of clinical medicine · 2023Review
- Challenges in posterior uveitis-tips and tricks for the retina specialist.Journal of ophthalmic inflammation and infection · 2023Review
- A COVID-19 perspective of Vogt-Koyanagi-Harada disease.Indian journal of ophthalmology · 2023Article
- Association of ZC3HAV1 single nucleotide polymorphisms with the susceptibility of Vogt-Koyanagi-Harada Disease.BMC medical genomics · 2023Article
- De novo Vogt-Koyanagi-Harada disease after vaccination for COVID-19, successfully treated with systemic steroid therapy and monitored with laser speckle flowgraphy.American journal of ophthalmology case reports · 2022Article
- Commentary: Dexamethasone intravitreal implant therapy in Vogt-Koyanagi-Harada disease.Indian journal of ophthalmology · 2022Article
- Probable Vogt-Koyanagi-Harada Disease after COVID-19 Vaccination: Case Report and Literature Review.Vaccines · 2022Article
- Manifestations of coronavirus infection disease-19 in anterior eye segment: An up-to-date review.Oman journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 23-year-old female presented with a 3-day history of bilateral (OU) diminution of vision 3 weeks after COVID-19 infection. Best corrected visual acuity (BCVA) was 20/30 in right eye and 20/40 in left eye. Anterior segment showed OU 1+ cells in anterior chamber and anterior vitreous face. Fundus OU showed disc hyperemia and multiple pockets of subretinal fluid (SRF), confirmed on optical coherence tomography. Fundus fluorescein angiography showed multiple pin point leaks suggestive of Vogt Koyanagi Harada disease. Oral corticosteroids 1 mg/kg/day were started. At 2-months' follow-up, her BCVA improved to 20/25 OU with complete resolution of SRF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.